EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2 ‐Positive Metastatic Breast Cancer: A Single‐Center Pooled Analysis

Jialin Lin iD, Qiao Li iD, Pin Zhang iD, Ying Fan, Ruigang Cai, Yang Luo, Bo Lan iD, Shanshan Chen, Jiani Wang iD, Hongnan Mo iD, Fei Ma, Jiayu Wang iD und 1 weitere

Thoracic Cancer · 2026-08 · 17 (15)

DOI: 10.1111/1759-7714.70362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 06.08.2026. Verfasst von Jialin Lin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijin…. Hauptthemen laut MEDLINE: Capecitabine, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding, Noncommunicable Chronic Disease-National Science and Technology Major Project, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Phase II and III trials have demonstrated progression‐free survival (PFS) benefits of pyrotinib plus capecitabine over lapatinib plus capecitabine in HER2‐positive metastatic breast cancer (MBC). However, long‐term overall survival (OS) data from a single‐center cohort remain limited. This pooled analysis compared OS between the two regimens and explored outcomes across prespecified subgroups.

Methods

We included patients with HER2‐positive MBC from our center enrolled in a Phase Ic study, a Phase II study, or the Phase III PHOEBE trial. The primary endpoint was OS. OS was analyzed using Kaplan–Meier estimates, log‐rank tests, and a multivariable Cox model adjusted for ECOG performance status, pathological grade, prior anti‐HER2 therapy, trastuzumab exposure duration, trastuzumab resistance, and prior chemotherapy lines. The proportional hazards assumption was assessed using Schoenfeld residuals. Exploratory subgroup analyses used prespecified categories.

Results

At data cutoff, 82 patients were included; 53 received pyrotinib plus capecitabine and 29 received lapatinib plus capecitabine. Baseline characteristics were comparable between groups. Median OS was 74.61 months (95% CI 41.10–not reached) with pyrotinib plus capecitabine and 30.98 months (26.12–50.76) with lapatinib plus capecitabine (log‐rank p = 0.0053). Cox models suggested a reduced risk of death with pyrotinib plus capecitabine. Subgroup analyses were exploratory and should be interpreted cautiously because several subgroup estimates were imprecise.

Conclusion

In this single‐center pooled analysis, pyrotinib plus capecitabine was associated with significantly longer OS than lapatinib plus capecitabine in patients with HER2‐positive MBC. These exploratory results are consistent with prior Phase II/III trials and provide evidence supporting the OS benefit of pyrotinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CapecitabineBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesAntineoplastic Combined Chemotherapy ProtocolsAcrylamidesLapatinibAminoquinolinesHumansFemaleMiddle AgedTyrosine Kinase InhibitorsNeoplasm Metastasis

Stichwörter der Autor:innen

HER2‐positiveTKImetastatic breast canceroverall survivalpyrotinib

Substanzen

pyrotinibCapecitabineErb-b2 Receptor Tyrosine KinasesAcrylamidesLapatinibAminoquinolinesERBB2 protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Beijing Key Laboratory of Innovative Drug R&D and Translational Research for Breast Cancer, Beijing, China.

ORCID-Profile: Jialin Lin, Qiao Li, Pin Zhang, Bo Lan, Jiani Wang, Hongnan Mo, Jiayu Wang, Binghe Xu

Förderung

  • National High Level Hospital Clinical Research Funding
  • Noncommunicable Chronic Disease-National Science and Technology Major Project
  • National Natural Science Foundation of China

Zitieren

APA

Lin, J., Li, Q., Zhang, P., Fan, Y., Cai, R., Luo, Y., Lan, B., Chen, S., Wang, J., Mo, H., Ma, F., Wang, J., & Xu, B. (2026). Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2 ‐Positive Metastatic Breast Cancer: A Single‐Center Pooled Analysis. Thoracic Cancer, 17(15). https://doi.org/10.1111/1759-7714.70362

Vancouver

Lin J, Li Q, Zhang P, Fan Y, Cai R, Luo Y, et al. Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2 ‐Positive Metastatic Breast Cancer: A Single‐Center Pooled Analysis. Thoracic Cancer. 2026;17(15). doi:10.1111/1759-7714.70362

BibTeX
@article{Lin2026,
  author = {Lin, Jialin and Li, Qiao and Zhang, Pin and Fan, Ying and Cai, Ruigang and Luo, Yang and Lan, Bo and Chen, Shanshan and Wang, Jiani and Mo, Hongnan and Ma, Fei and Wang, Jiayu and Xu, Binghe},
  title = {Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2 ‐Positive Metastatic Breast Cancer: A Single‐Center Pooled Analysis},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {15},
  doi = {10.1111/1759-7714.70362}
}
Kostenlos starten →